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Order Set Details
Clinical Overview Synopses
 ClinicalKey Clinical Overviews provide additional specific guidance for:
 Coronavirus: novel coronavirus (COVID-19) infection 
Guidance
Coronavirus (COVID-19), Clinical Overview Synopsis ~
KEY POINTS
COVID-19 (coronavirus disease 2019) is respiratory tract infection due to a novel coronavirus, SARS-
CoV-2 (initially called 2019-nCoV); as of March 11, 2020, extent of infection was declared pandemic by
the WHO
Virus is thought to be zoonotic in origin, but the animal reservoir is not yet known, and human-to-human
transmission is widespread
Infection ranges from asymptomatic to severe; symptoms include fever, cough, and (in moderate to
severe cases) dyspnea; disease may evolve over the course of a week or more from mild to severe.
Upper respiratory tract symptoms (eg, rhinorrhea, sore throat) are uncommon
A significant proportion of clinically evident cases are severe; the mortality rate among diagnosed cases is
generally about 2% to 3% but varies by country
Infection should be suspected based on presentation with a clinically compatible history and known or
likely exposure (eg, residence in or travel to an affected area within the past 14 days, exposure to a
known or suspected case, exposure to a health care setting in which patients with severe respiratory tract
infections are managed)
Chest imaging in symptomatic patients almost always shows abnormal findings, usually including bilateral
infiltrates; laboratory findings are variable but typically include lymphopenia and elevated lactate
dehydrogenase and transaminase levels
Diagnosis is confirmed by detection of viral RNA on polymerase chain reaction test of upper or lower
respiratory tract specimens or serum specimens
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There is no specific antiviral therapy, although compassionate use and trial protocols for several agents
are underway; treatment is largely supportive, consisting of supplemental oxygen and conservative fluid
administration
Most common complications are acute respiratory distress syndrome and septic shock; myocardial, renal,
and multiorgan failure have been reported
There is no vaccine available to prevent this infection; infection control measures are the mainstay of
prevention (ie, hand and cough hygiene; physical distancing; standard, contact, and airborne precautions
in health care)
URGENT ACTION
Triage screening is recommended at registration for medical care to identify patients with symptoms and
exposure history that suggest the possibility of COVID-19, and to promptly institute isolation measures
Patients with respiratory distress require prompt administration of supplemental oxygen; patients with
respiratory failure require intubation
Patients in shock require urgent fluid resuscitation and administration of empiric antimicrobial therapy to
cover possible bacterial pathogens and/or influenza
PITFALLS
It is probable that persons with prodromal or asymptomatic infection may spread infection, making
effective prevention more challenging; regardless, physical distancing is vital to slowing transmission
enough to avoid overwhelming health systems
Knowledge of this disease is incomplete and evolving; moreover, coronaviruses are known to mutate and
recombine often, presenting an ongoing challenge to our understanding and to clinical management
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Admission
 Admit to Hospital
 Admit to Observation
 Diagnosis: ___________________
 Condition: __________________
 Allergies: ___________________
 Assessment Scales
 Admission Criteria - Coronavirus 
Guidance
Admission Criteria, COVID-19 ~
Nonsevere pneumonia
Radiographic evidence of pneumonia; progressive clinical illness with indications for supplemental
oxygen and hydration; inadequate care at home
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CDC provides guidance for determining whether the home is a suitable venue and patient
and/or caregiver is capable of adhering to medical care recommendations and infection control
measures
Criteria for ICU admission
WHO provides criteria for severe pneumonia
Severe pneumonia characterized by tachypnea (respiratory rate greater than 30 breaths per
minute), severe respiratory distress, inadequate oxygenation (eg, SpO₂ less than 90%)
Pediatric criteria include central cyanosis or SpO₂ less than 90%; signs of severe respiratory distress
(eg, grunting, chest retractions); inability to drink or breastfeed; lethargy, altered level of consciousness,
seizures; severe tachypnea defined by age:
Younger than 2 months: 60 or more breaths per minute
Aged 2 to 11 months: 50 or more breaths per minute
Aged 1 to 5 years: 40 or more breaths per minute
Presence of severe complications (eg, septic shock, acute respiratory distress syndrome)
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Resuscitation Status
 Resuscitation Status: Do not resuscitate
 Advance Directive
 Document an advance care plan in chart or that a discussion was held; place copy of plan on chart,
if available 
Quality Measure
NQF 0326. Advance Care Plan
Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker
documented in the medical record or documentation in the medical record that an advance care plan was
discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an
advance care plan.
 
Steward: National Committee for Quality Assurance.
Use in Federal Program: Physician Quality Reporting System (PQRS).
Care Setting: Ambulatory Care: Clinician Office/Clinic, Hospital/Acute Care Facility, Other.
National Quality Forum-endorsed measure. Source
Published By: Elsevier
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Vital Signs and Monitors
 Vital Signs
 Vital Signs Every 8 hours
 Vital Signs Every 4 hours
 Weight Once
 Weight 1 time a day
 Height Once
 Monitoring
 Cardiac monitor
 Intake & Output
Activity
 Up ad lib
 Ambulate with assistance, 3 times a day
 Bed to chair, 3 times a day
 Bed rest with bathroom privileges
 Bed rest with commode
 Bed rest
Nursing
 Assessments
 Assess: Need for urinary catheter, every morning
 Point of Care Testing
 Fingerstick Glucose, Once
 Fingerstick Glucose, 4 times a day; before meals and at bedtime, or every 6 hours if NPO
 Notify Physician
 Notify Physician for Heart rate less than 50 bpm or greater than 120 bpm
 Notify Physician for Systolic BP less than 90 mmHg or greater than 160 mmHg
 Notify Physician for Temperature less than 35 C or greater than 38 C
 Notify Physician for Respiratory rate less than 10 breaths/min or greater than 24 breaths/min
 Notify Physician for O2 sat less than 90 %
 Notify Physician for Urine output less than 240 mL / 8 hr
 Tubes and Drains
 Minimize urinary catheter use and duration of use in all patients, particularly those at higher risk for
CAUTI or mortality from catheterization such as women, the elderly, and patients with impaired
immunity 
Guidance
Indwelling Urethral Catheter
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Consider indwelling urethral catheter use in the context of the following appropriate indications:
Acute urinary retention or bladder outlet obstruction
Need for accurate measurements of urinary output in critically ill patients
Perioperative use for selected surgical procedures in patients undergoing urologic or other surgery on
contiguous structures of the genitourinary tract
Anticipated prolonged duration of surgery (remove catheters inserted for this reason in postanesthesia
care unit)
Expectation that patient will receive diuretics or large-volume infusions during surgery
Need for intraoperative monitoring of urinary output
Need to assist healing of open sacral or perineal wounds in patients with incontinence
Requirement of prolonged immobilization (eg, because of a potentially unstable thoracic or lumbar
spine or multiple traumatic injuries such as pelvic fractures)
Improved comfort for end-of-life care 
Avoid indwelling catheter use in the following circumstances, as they are not appropriate indications for
indwelling catheter use:
Substitution for nursing care of a patient or resident with incontinence
Obtaining urine for culture or other diagnostic tests when the patient can voluntarily void
Prolonged postoperative duration without appropriate indications (eg, structural repair of urethra or
contiguous structures, prolonged effect of epidural anesthesia)
 
CDC. (2009 (2017 updates linked)). Guideline for the Prevention of Catheter-Associated Urinary Tract
Infections. Source
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 Indwelling urinary catheter to gravity drainage
 Discontinue indwelling urinary catheter
 Precautions 
Guidance
Transmission-Based Precautions, COVID-19 ~
Standard, contact, and airborne precautions should be implemented as soon as the diagnosis is suspected
Immediately provide the patient with a face mask (or, if supplies are critically low, at least a cloth face
cover) to reduce droplet spread and place the patient in a closed room pending further evaluation and
disposition decisions. The closed room will ideally be one with structural and engineering safeguards
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against airborne transmission (eg, negative pressure, frequent air exchange), but in the high-prevalence
stages of the pandemic (with crowded hospitals), reserve negative pressure isolation rooms for the
greatest needs (ie, aerosol-generating procedures; tuberculosis, measles, and varicella)
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Transmission-Based Precautions
Categorize transmission-based precautions as follows:
Assign a transmission-based precautions category if there is strong evidence of person-to-person
transmission via one or more of:
Droplet
Contact
Airborne routes
Patient factors (e.g., diapered infants, diarrhea, draining wounds) that increase the risk of
transmission
Assign standard precautions if there is one of the following:
No evidence of person-to-person transmission by droplet, contact, or airborne routes
A low risk of person-to-person transmission and no evidence of health-care-associated
transmission
Also assign standard precautions to blood-borne pathogens (e.g., hepatitis B and C viruses, HIV) per
universal precaution recommendations from the CDC
Assume that every person is potentially infected or colonized with an organism that could be transmitted in
the healthcare setting and apply standard infection control practices during the delivery of health care
 
For a list of the type and duration of precautions recommended for selected infections and conditions, click here
 
Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases
(NCEZID), Division of Healthcare Quality Promotion (DHQP). (2019). Isolation Precautions. Source
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 Precaution: Airborne
 Precaution: Contact
 Precaution: Droplet
 Precaution: Standard
 Patient Education
 Patient education: Infection Education 
Guidance
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At Home Monitoring, COVID-19 ~
Patients who do not require admission should self-monitor temperature and symptoms, and they should return
for reevaluation if symptoms worsen; deterioration may occur a week or more into the course of illness
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Household Members and Caregivers, COVID-19 ~
Household members/caregivers should:
Ideally, wear face mask, gown, and gloves when caring for patient, and remove and discard all when
leaving the room (do not reuse); however, if some of these supplies are absent, wear cloth face cover
and scrupulously wash hands and laundry
Dispose of disposable items in a container lined with a trash bag that can be removed and tied
off or sealed before disposal in household trash
Wash hands for at least 20 seconds after all contact; an alcohol-based hand sanitizer is acceptable if
soap and water are not available
Not share personal items such as towels, dishes, or utensils before proper cleaning
Wash laundry and high-touch surfaces frequently
Wear disposable gloves to handle dirty laundry and use highest possible temperatures for
washing and drying, based on washing instructions on the items
Clean surfaces with diluted bleach solution or an EPA-approved disinfectant
Restrict contact to minimum number of caregivers and, in particular, ensure that persons with
underlying medical conditions are not exposed to the patient
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
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 Patient education: Airborne Precautions
 Patient education: Responsibilities of provider concerning notification, including parent, guardian,
public health authorities
 Patient education: Tobacco/Second-Hand Smoke Counseling  
Guidance
Counseling, Smoking Cessation/Tobacco Withdrawal
According to systematic reviews of smoking cessation programs for hospitalized patients:
High-intensity behavioral counseling beginning during hospitalization and continuing for at least 1
month after discharge was more effective than either usual care or less intensive counseling
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The addition of nicotine replacement therapy resulted in further benefit
Preoperative smoking interventions may reduce postoperative morbidity
 
Thomsen T, Villebro N, Møller AM. Interventions for preoperative smoking cessation. Cochrane Database Syst
Rev. 2014;3, CD002294. Source
 
Rigotti NA, Clair C, Munafò MR, Stead LF. Interventions for smoking cessation in hospitalised patients.
Cochrane Database Syst Rev. 2012;5(5), CD001837. Source
Published By: Elsevier
Quality Measure
NQF 1651; NQF 1654; NQF 1656. Inpatient tobacco cessation bundle, includes discharge
NQF 1651; NQF 1654; and NQF 1656 are bundled, inpatient quality measures from the Joint Commission
related to tobacco use screening and treatment, and referral to treatment at discharge.
 
1.)  NQF 1651. TOB-1: Tobacco Use Screening. 
Hospitalized patients aged >18 years, who are screened during the hospital stay for tobacco use
(cigarettes, smokeless tobacco, pipe and cigars) within the past 30 days. This measure is intended to
be used as part of a set of linked measures addressing Tobacco Use. Source
 
2.)  NQF 1654. TOB-2: Tobacco Use Treatment Provided or Offered and the subset measure TOB-2a
Tobacco Use Treatment. 
The measure is reported as an overall rate, which includes all hospitalized patients aged >18 years, to
whom tobacco use treatment was provided during the hospital stay, or offered and refused; and a
second rate, a subset of the first, which includes only those patients who received tobacco use
treatment during the hospital stay. These measures are intended to be used as part of a set of
measures addressing Tobacco Use. 
TOB-2: The number of patients who received or refused practical counseling to quit AND received or
refused FDA-approved cessation medications.
TOB-2a: The number of patients who received practical counseling to quit AND received FDA-
approved cessation medications. Source
 
3.)  NQF1656. TOB-3: Tobacco Use Treatment Provided or Offered at Discharge and the subset
measure
TOB-3a: Tobacco Use Treatment at Discharge. The measure is reported as an overall rate which
includes all hospitalized patients aged >18 years, to whom tobacco use treatment was provided, or
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offered and refused, at the time of hospital discharge; and a second rate, a subset of the first, which
includes only those patients who received tobacco use treatment at discharge. Treatment at discharge
includes a referral to outpatient counseling and a prescription for one of the FDA-approved tobacco
cessation medications. These measures are intended to be used as part of a set of linked measures
addressing Tobacco Use. 
TOB-3: The number of patients who received or refused evidence-based outpatient counseling AND
received or refused a prescription for FDA-approved cessation medication at discharge.
TOB-3a: The number of patients who were referred to evidence-based outpatient counseling AND
received a prescription for FDA-approved cessation medication at discharge. Source
 
Steward: Joint Commission. National Quality Strategy Priorities: Health and Well-Being.
Care Setting: Hospital/Acute Care Facility.
National Quality Forum-endorsed measures.
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Respiratory
 Oxygen Administration 
Guidance
Oxygenation and Ventilation, COVID-19 ~
WHO provides specific guidance for oxygenation, and ventilation
Begin supplemental oxygen when O₂ saturation falls below 90% to 92%
Nasal cannula at 5 L/minute or face mask with reservoir bag at 10 to 15 L/minute
Titrate to reach SpO₂ of 94% or more initially
Once stable, target SpO₂ of 90% or higher in nonpregnant adults; 92% or higher in pregnant
patients
In most children the target SpO₂ is 90% or greater; for those who require urgent resuscitation (eg,
those with apnea or obstructed breathing, severe respiratory distress, central cyanosis, shock,
seizures, or coma), a target SpO₂ of 94% or higher is recommended
High-flow nasal oxygen or noninvasive ventilation has been used to achieve adequate oxygenation in
some patients
High-flow nasal oxygen is recommended by Surviving Sepsis Campaign and NIH for COVID-19
patients who develop hypoxemic respiratory failure despite conventional oxygen therapy; there is
some evidence that it averts the need for intubation and mechanical ventilation. Noninvasive
positive pressure ventilation may be used if high-flow nasal oxygen is not available
However, there is concern that these techniques may result in higher risk of aerosolization of the
virus. Additionally, sudden deterioration may require emergent intubation, which is associated with
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more risk to both patient and provider. Therefore, some authorities reserve these options for
settings in which airborne precautions can be taken and close monitoring provided
Mechanical ventilation may become necessary for patients in whom oxygenation targets cannot be met
with less invasive measures or who cannot maintain the work of breathing
Recommended settings are tidal volume of 4 to 8 mL/kg (predicted body weight) and inspiratory
pressures less than 30 cm H₂O
In children, tidal volumes of 5 to 8 mL/kg (predicted body weight) for preserved lung compliance
and 3 to 6 mL/kg for poor compliance; inspiratory pressures should be less than 28 cm H₂O
Use of PEEP may be necessary in patients with acute respiratory distress syndrome. Optimal
regimen is not clearly defined, although guidelines suggest higher pressures (eg, more than 10 cm
H₂O) rather than lower pressures. A protocol is available from ARDSnet
For patients with moderate to severe acute respiratory distress syndrome, prone positioning for 12
to 16 hours/day is recommended
Lateral decubitus position for pregnant women
Extracorporeal membrane oxygenation has been used in severely ill patients, and it can be considered if
resources and expertise are available
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
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 Oxygen Nasal cannula 5 L/Minute ; titrate to oxygen saturation 94% or greater ; Step 1
 Oxygen Nasal cannula 5 L/Minute ; titrate to oxygen saturation 90% or greater ; When stable, Step
2 for Non-pregnant adults
 Oxygen Nasal cannula 5 L/Minute ; titrate to oxygen saturation 92% or greater ; When stable, Step
2 for Pregnant Adults
 Monitoring
 Oxygen saturation Every 8 hours
 O2 saturation monitor
Diet
 Diet: Regular
 Diet: Regular (Low saturated fat and cholesterol, No added salt)
 Diet: Regular (consistent carbohydrate)
 Diet: Mechanical/dental soft
 Diet: Full liquids
 Diet: Clear liquids
 Diet: Nothing by mouth
 Diet: Nothing by mouth, except medications
 Diet: Nothing by mouth (After Midnight)
Intravenous Fluids 
Guidance
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Intravenous Fluids, COVID-19 ~
WHO provides specific guidance for fluid management
Fluid management
Overhydration should be avoided, because it may precipitate or exacerbate acute respiratory distress
syndrome
In patients with shock:
Administration of crystalloids is recommended (preferably buffered/balanced; eg, lactated Ringer
solution); solutions such as hydroxyethyl starches, gelatins, dextrans, and albumin are not
recommended according to Surviving Sepsis Campaign guideline on managing critically ill adults
with COVID-19. WHO provides the following guidance:
Adults: administer 250 to 500 mL over the first 15 to 30 minutes; goal is mean arterial
pressure of 60 to 65 mm Hg (if invasive pressure monitoring is available)
Children: 10 to 20 mL/kg bolus over the first 30 to 60 minutes
If there is no response to fluid bolus or if signs of fluid overload exist, discontinue or reduce
fluid administration
For patients who respond to initial bolus and are without evidence of fluid overload, titrate
continued fluid to achieve improvement in clinical signs (capillary refill, heart rate, tactile
temperature of extremities, palpable pulses), urine output (0.5 mL/kg/hour in adults, 1
mL/kg/hour in children), and hemodynamic parameters (mean arterial pressure more than
65 mm Hg in adults)
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
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 Saline Lock
 Saline Lock
 Intravenous Bolus
 IV Bolus: Sodium Chloride 0.9%; 500 mL
 IV Bolus: Sodium Chloride 0.9%; 1000 mL
 Intravenous Infusion
 IV infusion: Sodium Chloride 0.9% at 100 mL/hr
 IV infusion: Dextrose 5% and Sodium Chloride 0.45% at 100 mL/hr
 IV infusion: Dextrose 5% and Sodium Chloride 0.45% with Potassium Chloride 20 mEq/L at 100
mL/hr
 IV infusion: Lactated Ringer's Solution at 100 mL/hr
Medications 
Guidance
COVID-19 Medication Guidance, COVID-19 ~
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At present, no specific antiviral agent is approved for treatment of this infection. Several existing antiviral agents
are being used under clinical trial and compassionate use protocols based on in vitro activity (against this or
related viruses) and on limited clinical experience
Chloroquine and hydroxychloroquine have been used in China and South Korea, reportedly with favorable
results, although details are lacking and follow-up studies have been less encouraging. Further trials are
underway in Europe and the United States. Both are associated with QT prolongation and risk of cardiac
arrhythmias
Azithromycin has been used in combination with hydroxychloroquine in some protocols; however,
azithromycin is also associated with cardiac arrhythmias, and the possible increased risk posed by
the combination must be considered
In the United States, emergency use authorization for chloroquine and hydroxychloroquine has
been issued by FDA to permit use in hospitalized adult and adolescent patients for whom a clinical
trial is not available or feasible
Surviving Sepsis Campaign guideline on managing critically ill adults with COVID-19 states that
data are insufficient to make a recommendation on the use of these agents
In patients admitted to hospital with COVID-19, Infectious Diseases Society of America
recommends hydroxychloroquine or chloroquine in the context of a clinical trial, and in combination
with azithromycin only in the context of a clinical trial, based on evidence of very low certainty
NIH guidelines do not recommend for or against chloroquine or hydroxychloroquine because of
insufficient data; they recommend against the addition of azithromycin to hydroxychloroquine. The
guidelines note that when chloroquine or hydroxychloroquine is used, patients must be monitored
for adverse effects, particularly prolonged QTc interval
Remdesivir is an experimental antiviral agent with significant in vitro activity against coronaviruses and
some evidence of efficacy in an animal model of MERS
Although not FDA-approved, remdesivir is in use for the indication; FDA has issued an emergency
use authorization for use of IV remdesivir to treat hospitalized patients with COVID-19 who have
severe disease, defined as SpO₂ of 94% or less on room air, requiring supplemental oxygen,
mechanical ventilation, or extracorporeal membrane oxygenation
Preliminary results of the Adaptive COVID-19 Treatment Trial, a placebo-controlled
randomized trial in 1063 patients, showed a statistically significant improvement in time to
recovery and a nonsignificant trend in lower mortality; several other trials remain active, as
well
Lopinavir-ritonavir is FDA-approved for treatment of HIV infection. It has been used for other coronavirus
infections; it was used empirically for SARS and is being studied in the treatment of MERS
In China this combination is used in conjunction with interferon alfa for treatment of some patients
with COVID-19
Surviving Sepsis Campaign guideline on managing critically ill adults with COVID-19
recommends against use of recombinant interferons, based on lack of data in COVID-19
and on data from studies on MERS showing lack of efficacy
NIH COVID-19 treatment guideline recommends against use of interferon except in clinical
trials
A trial in 199 patients with COVID-19 comparing lopinavir-ritonavir with standard care did not show
a significant difference in time to improvement or in mortality at 28 days, nor were there differences
in duration of viral RNA in oropharyngeal specimens
NIH COVID-19 treatment guideline and Surviving Sepsis Campaign guideline on managing
critically ill adults with COVID-19 recommend against use of lopinavir-ritonavir
In patients admitted to hospital with COVID-19, Infectious Diseases Society of America
recommends lopinavir-ritonavir only in the context of a clinical trial
Immunomodulators are also being investigated for mitigation of cytokine release syndrome believed to be
a factor in severe acute respiratory distress syndrome and shock in COVID-19
(eg, tocilizumab and sarilumab are both monoclonal antibodies against interleukin-6 receptor)
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Surviving Sepsis Campaign guideline on managing critically ill adults with COVID-19 states that
data are insufficient to make a recommendation on the use tocilizumab; the guideline did not
evaluate other monoclonal antibodies
In patients admitted to hospital with COVID-19, Infectious Diseases Society of America
recommends tocilizumab only in the context of a clinical trial, based on evidence of very low
certainty
NIH COVID-19 treatment guideline states that data are insufficient to recommend for or against
use of these agents
Studies on the therapeutic efficacy of convalescent plasma are underway in various countries. In the
United States, authorization must be obtained through FDA
Surviving Sepsis Campaign guideline on managing critically ill adults with COVID-19 suggests that
convalescent plasma not be used on the basis of data in other viral infections, lack of data in
COVID-19, and uncertainties about safety
In patients admitted to hospital with COVID-19, Infectious Diseases Society of America
recommends convalescent plasma in the context of a clinical trial, based on evidence of very low
certainty
NIH COVID-19 treatment guideline states that data are insufficient to recommend for or against
use of convalescent plasma or hyperimmune immunoglobulin
Information on therapeutic trials and expanded access is available at ClinicalTrials.gov
Corticosteroid therapy is not recommended for viral pneumonia but is suggested by some authorities for
COVID-19 patients with refractory shock or acute respiratory distress syndrome
Surviving Sepsis Campaign guideline on managing critically ill adults with COVID-19 supports
using corticosteroids in mechanically ventilated patients with COVID-19 and acute respiratory
distress syndrome (but not those with respiratory failure in the absence of that syndrome) and in
patients with COVID-19 and refractory shock; short-course, low-dose regimens are preferred
Similarly, Infectious Diseases Society of America suggests against the use of corticosteroids in
hospitalized patients with COVID-19 and pneumonia, but it recommends their use in the context of
a clinical trial for patients with COVID-19 and acute respiratory distress syndrome
NIH COVID-19 treatment guideline recommends against routine use in mechanically ventilated
patients without acute respiratory distress syndrome, notes insufficient data to recommend for or
against it in mechanically ventilated patients with that syndrome, and recommends low-dose
corticosteroids in patients with refractory shock
FDA is investigating a controversy that has arisen regarding the use of NSAIDs in patients with COVID-
19; however, there is no published evidence connecting the use of NSAIDs with worsening COVID-19
symptoms
NIH COVID-19 treatment guideline recommends that use of acetaminophen and NSAIDs in
patients with COVID-19 should not differ from that in patients without COVID-19
Until a diagnosis of COVID-19 is confirmed by polymerase chain reaction test, appropriate antiviral or
antimicrobial therapy for other viral pathogens (eg, influenza virus) or bacterial pathogens should be
administered in accordance with the site of acquisition (hospital or community) and epidemiologic risk
factors
Additionally, Surviving Sepsis Campaign guideline on managing critically ill adults with COVID-19
supports use of empiric antimicrobial therapy in mechanically ventilated patients with COVID-19
and respiratory failure, with daily consideration for de-escalation
Otherwise, treatment is largely supportive and includes oxygen supplementation and conservative fluid
support
Role of low-molecular-weight heparin (beyond standard prophylaxis indications) is being studied,
and some authorities recommend use of prophylactic regimens in any patient with COVID-19 and
blood markers indicating coagulopathy (eg, marked elevation of D-dimer level, prolonged
prothrombin time, platelet count of 100,000 cells/mm³ or lower, fibrinogen level less than 2 g/L)
Management of septic shock includes use of vasopressors if fluid administration does not restore
adequate perfusion. Surviving Sepsis Campaign, NIH COVID-19 treatment guideline, and WHO provide
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guidance specific to the treatment of shock in patients with COVID-19
In adults, begin with norepinephrine; epinephrine or vasopressin are preferred as second line over
dopamine if norepinephrine is unavailable
Hemodynamic goal: mean arterial pressure of 60 to 65 mm Hg
In patients who do not respond adequately to usual doses of norepinephrine, Surviving Sepsis
Campaign guideline on managing critically ill adults with COVID-19 recommends adding
vasopressin rather than further titrating norepinephrine
For patients with COVID-19, refractory shock despite fluid and norepinephrine, and evidence of
cardiac dysfunction, Surviving Sepsis Campaign guideline on managing critically ill adults with
COVID-19 recommends adding dobutamine rather than further titrating norepinephrine
In children, epinephrine is considered the first line agent, and norepinephrine may be added if
necessary
Drug therapy
Antimalarial agents
Chloroquine
Infants, Children, and Adolescents weighing less than 50 kg : Efficacy and optimal
dosing not established; however, based on extrapolation from pediatric dosing for
other indications and comparative doses to the adult dosing regimen suggested for
COVID-19, 8.3 mg (5 mg base)/kg/dose PO twice daily [Max: 500 mg/dose (300 mg
base/dose)] is being used in limited pediatric dosing protocols; a 10-day course is
being used in adult patients.
Adolescents weighing 50 kg or more : Data are limited; efficacy has not been
established. 1000 mg PO on day 1 then 500 mg PO daily for 4 to 7 days suggested
by FDA EUA statement. Based on extrapolation from pediatric dosing for other
indications and comparative doses to the adult dosing regimen suggested for
COVID-19, 8.3 mg (5 mg base)/kg/dose PO twice daily [Max: 500 mg/dose (300 mg
base/dose)] is being used in limited pediatric dosing protocols; a 10-day course is
being used in adult patients.
Adults weighing less than 50 kg : Data are limited; efficacy has not been
established. 500 mg PO twice daily for 10 days is being evaluated alone and in
combination.
Adults weighing 50 kg or more : Data are limited; efficacy has not been established.
1000 mg PO on day 1 then 500 mg PO daily for 4 to 7 days suggested by FDA
EUA statement. 500 mg PO twice daily for 10 days is also being evaluated alone
and in combination.
Hydroxychloroquine
Infants, Children, and Adolescents weighing less than 50 kg : Efficacy and optimal
dosing not established; however, based on extrapolation from pediatric dosing for
other indications and comparative doses to adult dosing regimens suggested for
COVID-19, doses of 6.5 mg (5 mg base)/kg/dose PO every 12 hours [Max: 400
mg/dose (310 mg base/dose)] for 2 doses, then 3.25 mg (2.5 mg base)/kg/dose
every 12 hours [Max: 200 mg/dose (155 mg base/dose)] are being used in limited
pediatric dosing protocols; a 5- to 20-day course is being used in adult patients.
Adolescents weighing 50 kg or more : Data are limited; efficacy has not been
established. 800 mg PO on day 1 then 400 mg PO daily for 4 to 7 days suggested
by FDA EUA statement. Based on extrapolation from pediatric dosing for other
indications and comparative doses to adult dosing regimens suggested for COVID-
19, doses of 6.5 mg (5 mg base)/kg/dose PO every 12 hours [Max: 400 mg/dose
(310 mg base/dose)] for 2 doses, then 3.25 mg (2.5 mg base)/kg/dose every 12
hours [Max: 200 mg/dose (155 mg base/dose)] are being used in limited pediatric
dosing protocols; a 5- to 20-day course is being used in adult patients.
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Adults weighing less than 50 kg : Data are limited; efficacy has not been
established. Dosing regimens, alone and in combination, are being evaluated,
including 400 mg PO twice daily on day 1 then 200 mg PO twice daily for 4 days;
200 mg PO twice daily for 5 to 20 days; and 200 mg PO three times daily for 10
days. Additional clinical evaluation is needed.
Adults weighing 50 kg or more : Data are limited; efficacy has not been established.
800 mg PO on day 1 then 400 mg PO daily for 4 to 7 days suggested by FDA EUA
statement. Other dosing regimens, alone and in combination, are being evaluated,
including 400 mg PO twice daily on day 1 then 200 mg PO twice daily for 4 days;
200 mg PO twice daily for 5 to 20 days; and 200 mg PO three times daily for 10
days. Additional clinical evaluation is needed.
Monoclonal antibodies
Tocilizumab
Tocilizumab Solution for injection; Adults: Available data are limited, and efficacy
has not been established. Due to a lack of clinical data, the NIH COVID-19
treatment guidelines do not recommend for or against the use of IL-6 receptor
inhibitors, such as tocilizumab. 4 to 8 mg/kg/dose (Usual dose: 400 mg; Max dose:
800 mg) IV once is being evaluated in combination with antiviral therapy. A second
dose 8 to 12 hours after the first infusion may be considered. One protocol
suggests a possible third dose 16 to 24 hours after the first dose.
Sarilumab
Sarilumab Solution for injection; Adults: Efficacy has not been established. 200 mg
IV or subcutaneously once or 400 mg IV once is being evaluated in combination
with antiviral therapy.
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
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 Analgesics 
Guidance
NSAIDs in Older Adults
Oral NSAIDs:
Increased risk of gastrointestinal bleeding or peptic ulcer disease in high-risk groups, including those >75
years or taking oral or parenteral corticosteroids, anticoagulants, or antiplatelet agents (Quality of
evidence: moderate; Strength of recommendation: Strong)
May exacerbate existing ulcers or cause new/additional ulcers 
Avoid unless other alternatives are not effective and patient can take gastroprotective agent
Avoid ketorolac in older adults due to the increased risk of gastrointestinal bleeding/peptic ulcer disease
and acute kidney injury in older adults (Quality of evidence: moderate; Strength of recommendation:
Strong)
Compared to patients younger than 65 years of age, the mean elimination half-life of ketorolac in
the elderly is prolonged (7 hours after an IM dose and 6.1 hours after an oral dose)
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Use with caution in patients with heart failure who are asymptomatic and avoid in patients with
symptomatic heart failure due to the potential to promote fluid retention and/or exacerbate heart failure
(Quality of evidence: moderate; Strength of recommendation: Strong)
Avoid in patients with chronic kidney disease stage 4 or higher (creatinine clearance <30 mL/min) as they
may increase risk of acute kidney injury and further decline of renal function (Quality of evidence:
moderate; Strength of recommendation: Strong)
This includes patients at risk for renal failure due to hypovolemia (dehydration)
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019
Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc.
2019;67(4), 674–694. Source
Ketorolac Drug Monograph. ClinicalKey.  
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 Acetaminophen Oral Tablet; 650 mg Every 4 hours (PRN: Pain, mild); Do not exceed 4000 mg
acetaminophen in 24 hours from all sources
 Acetaminophen 325 MG / HYDROcodone Bitartrate 5 MG Oral Tablet; 1 tablet(s) Every 4 hours
(PRN: Pain, moderate); Do not exceed 4000 mg acetaminophen in 24 hours from all sources
 Acetaminophen 325 MG / oxyCODONE Hydrochloride 5 MG Oral Tablet; 1 tablet(s) Every 6 hours
(PRN: Pain, moderate); Do not exceed 4000 mg acetaminophen in 24 hours from all sources
 Morphine Intravenous Injectable Solution; 2 mg Every 4 hours (PRN: pain, severe)
 HYDROmorphone Intravenous Injectable Solution; 0.5 mg Every 4 hours (PRN: pain, severe)
 Antacids
 Aluminum Hydroxide 40 MG/ML / Magnesium Hydroxide 40 MG/ML / Simethicone 4 MG/ML Oral
Suspension; 10 mL Every 6 hours (PRN: Heartburn)
 Famotidine Oral Tablet; 20 mg Every 12 hours
 Famotidine Intravenous Injectable Solution; 20 mg Every 12 hours
 pantoprazole Oral Delayed Release Tablet; 40 mg Every 24 hours
 pantoprazole Intravenous Injectable Solution; 40 mg Every 24 hours
 Antidiarrheal Agents
 Loperamide Oral Tablet ; 4 mg Once
 Antiemetics
 Ondansetron Oral Tablet; 4 mg Every 8 hours (PRN: Nausea/vomiting)
 Ondansetron Intravenous Injectable Solution; 4 mg Every 8 hours (PRN: Nausea/vomiting)
 Antipyretics
 Acetaminophen Oral Tablet; 650 mg Every 4 hours (PRN: Temperature greater than 38 degree
celsius); Do not exceed 4000 mg acetaminophen in 24 hours from all sources
 Acetaminophen Rectal Suppository; 650 mg Every 4 hours (PRN: Temperature greater than 38
degree celsius); Do not exceed 4000 mg acetaminophen in 24 hours from all sources
 Anxiolytics, Sedatives, and Hypnotics
 Benzodiazepines may increase the risk of falls 
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Guidance
Benzodiazepine Risks, Elderly
Avoid benzodiazepines in older adults (Quality of evidence: moderate; Strength of recommendation: strong)
Older adults have increased sensitivity to benzodiazepines and decreased metabolism of long-acting
agents
In general, all benzodiazepines increase risk of cognitive impairment, delirium, falls, fractures, and
motor vehicle crashes in older adults
May be appropriate for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine
withdrawal, ethanol withdrawal, severe generalized anxiety disorder, and periprocedural anesthesia 
 
Nonbenzodiazepine benzodiazepine receptor agonist hypnotics have adverse events similar to those of
benzodiazepines in older adults (eg, delirium, falls, fractures) (Quality of evidence: moderate; Strength of
recommendation: strong)
 
 
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society
2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr
Soc. 2019;67(4), 674–694. Source
Published By: Elsevier
 LORazepam Oral Tablet; 1 mg Every 8 hours (PRN: Anxiety)
 LORazepam Intravenous Injectable Solution; 0.5 mg Every 8 hours (PRN: Anxiety)
 Laxatives/Stool Softeners
 Bisacodyl Oral Tablet; 10 mg Every 24 hours (PRN: Constipation); Administer up to 3 times a week
of either suppository or oral tablet
 Bisacodyl Rectal Suppository; 10 mg Every 24 hours (PRN: Constipation); Administer up to 3 times
a week of either suppository or oral tablet
 Docusate Oral Capsule; 100 mg Every 24 hours
 Magnesium Hydroxide 80 MG/ML Oral Suspension; 30 mL At bedtime (PRN: Constipation)
 POLYETHYLENE GLYCOL 3350 Oral Solution; 17 grams Every 24 hours (PRN: Constipation)
 Immunizations 
Guidance
Immunization Schedule, Aged 19 Years or Older
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Table 1. Recommended Adult Immuniz
ages 19 years or older, United States, 2
Always make recommendations by determining needed vaccines based on
and other indications (Table 2), and reviewing special situations (Notes).
Table 1. By age
Table 2. By indications
Schedule Changes & Guidance
Resources for health care providers
Resources for adults
Download Schedules App
8.5″x11″ print color  [6 pages]
8.5″x11″ print black and white  [6 pages]
Compliant version of this schedule


Vaccines in the Adult Immunization Schedule
Learn how to display current schedules from your website.
Hard copies of the schedule are available for free using the CDC-info o
Download Schedules App
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 Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases
(NCIRD). (2020). Recommended immunization schedule for adults aged 19 years or older, United States. Source
Published By: Elsevier
 Influenza vaccine Injectable Suspension Intramuscular Injectable Suspension; 0.5 mL Once 
Quality Measure
NQF 1659. Influenza Immunization, Inpatient, 6 Months and Older, discharge
Inpatients aged >6 months, discharged during October, November, December, January, February or March,
who are screened for influenza vaccine status and vaccinated prior to discharge, if indicated. 
 
Steward: Centers for Medicare & Medicaid Services.
Use in Federal Program: Hospital Inpatient Quality Reporting. 
Care Setting: Hospital/Acute Care Facility . 
National Quality Forum-endorsed measure. Source
Published By: Elsevier
 Pneumococcal polysaccharide vaccine 23 (PPSV23) Injectable Solution Intramuscular Injectable
Solution; 0.5 mL Once
 Pneumococcal conjugate vaccine 13 (PCV13) Prefilled Syringe Intramuscular Prefilled Syringe; 0.5
mL Once
 acellular pertussis vaccine, inactivated / diphtheria toxoid vaccine, inactivated / tetanus toxoid
vaccine, inactivated Intramuscular Injection; 0.5 mL Once
 diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Intramuscular Injection;
0.5 mL Once
Legend
Recommended vaccination for adults who meet age requirement, lack documentat
Recommended vaccination for adults with an additional risk factor or another indic
Recommended vaccination based on shared clinical decision-making
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DVT Prophylaxis  
Guidance
Prevention of VTE in Hospitalized Acutely Ill Medical Patients
According to American College of Chest Physicians Practice Guidelines:
Use anticoagulant thromboprophylaxis with low-molecular-weight heparin (LMWH), low-dose
unfractionated heparin (UFH) 2 or 3 times per day, or fondaparinux in acutely ill hospitalized medical
patients at increased risk of thrombosis
Do not use pharmacologic or mechanical prophylaxis in acutely ill, hospitalized medical patients at low risk
of thrombosis. (Grade: 1B)
Do not use anticoagulant thromboprophylaxis for acutely ill hospitalized medical patients who are bleeding
or at high risk for bleeding. (Grade: 1B)
Use mechanical thromboprophylaxis with graduated compression stockings (grade: 2C) or intermittent
pneumatic compression (Grade: 2C) rather than no mechanical thromboprophylaxis in acutely
ill hospitalized medical patients at increased risk of thrombosis who are bleeding or at high risk of major
bleeding. When bleeding risk decreases and venous thromboembolism risk persists, substitute
pharmacologic thromboprophylaxis for mechanical thromboprophylaxis. (Grade: 2B)
Do not extend the duration of thromboprophylaxis beyond the period of patient immobilization or acute
hospital stay in acutely ill hospitalized medical patients who receive an initial course of
thromboprophylaxis. (Grade: 2B)
The ACCP recommends the Padua Prediction Score for judging hospitalized patients’ risk. The Padua Prediction
Score assigns points to
the 11 risk factors below. A cumulative score of 4 points or higher constitutes a high risk of venous thromboembolis
Padua Prediction Score is available here.
 
American Society of Hematology (ASH) Guidelines
Acutely ill medical patients:  ASH suggests using UFH, LMWH, or fondaparinux rather than no parenteral
anticoagulant. (Conditional recommendation, low certainty in the evidence of effects)
Critically ill medical patients:  AHS recommends using UFH or LMWH over no UFH or LMWH (strong
recommendation, moderate certainty in the evidence of effects) and suggests using LMWH over UFH.
(Conditional recommendation, moderate certainty in the evidence of effects)
DOAC vs LMWH in acutely ill medical patients:
In acutely ill hospitalized medical patients, the ASH guideline panel recommends using LMWH
over DOACs for VTE prophylaxis. (Strong recommendation, moderate certainty in the evidence of
effects)
In acutely ill hospitalized medical patients, the ASH guideline panel recommends inpatient VTE
prophylaxis with LMWH only, rather than inpatient and extended-duration outpatient VTE
prophylaxis with DOACs. (Strong recommendation, moderate certainty in the evidence of effects)
The American College of Physicians (ACP) guideline differ slightly from those of the American College of Chest
Physicians, particularly with respect to the use of mechanical prophylaxis. According to the ACP:
Individually assess the risks of thromboembolism and bleeding in medical patients before administering
prophylaxis. (Strong recommendation, moderate-quality evidence)
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Administer pharmacologic prophylaxis with heparin or a related drug in medical patients (including those
with stroke), unless the risk of bleeding exceeds the likely benefits.(Strong recommendation, moderate-
quality evidence)
Do not administer mechanical prophylaxis with graduated compression stockings. (Strong
recommendation, moderate-quality evidence). In patients at high risk for bleeding events or in whom
heparin is contraindicated for other reasons, intermittent pneumatic compression may be a reasonable
option
 
The National Institute for Health and Care Excellence (NICE) guideline recommends to:
 Screen patients with an approved tool. The NICE recommended tool can be found here
Offer pharmacological VTE prophylaxis for a minimum of 7 days to acutely ill medical patients whose risk
of VTE outweighs their risk of bleeding:
Use low-molecular-weight heparin (LMWH) as first-line treatment
If LMWH is contraindicated use fondaparinux sodium
 If using pharmacological VTE prophylaxis for people with renal impairment choose either LMWH or
unfractionated heparin (UFH)
 If needed, reduce the dose of LMWH and UFH for people with renal impairment. Base the decision on
multidisciplinary or senior opinion, or locally agreed protocols
Specific recommendations for people with cancer, under palliative care, admitted to critical care, and who have
psychiatric illness are found in the NICE guideline.
 
Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P . Clinical Guidelines Committee of the American
College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline
from the American College of Physicians. Ann Intern Med. 2011;155(9), 625-632. Source
 
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians
Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl), 7S-47S. Source
 
National Institute for Health and Care Excellence (NICE). (2019). Venous thromboembolism in over 16s: reducing
the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Source
 
Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for
management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.
Blood Adv. 2018;2(22), 3198-3225. Source
Published By: Elsevier
Quality Measure
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NQF 0371. Venous Thromboembolism Prophylaxis
This measure assesses the number of patients who received venous thromboembolism prophylaxis or have
documentation why no venous thromboembolism prophylaxis was given the day of or the day after hospital
admission or surgery end date for surgeries that start the day of or the day after hospital admission. This measure
is part of a set of six nationally implemented prevention and treatment measures that address
venous thromboembolism .
Exclusions:
Patients less than 18 years of age
Patients who have a length of stay (LOS) less than two days and greater than 120 days
Patients with Comfort Measures Only documented on day of or day after hospital arrival
Patients enrolled in clinical trials related to VTE
Patients who are direct admits to intensive care unit (ICU), or transferred to ICU the day of or the day after
hospital admission with ICU LOS greater than or equal to one day
Patients with ICD-9-CM Principal Diagnosis Code of Mental Disorders or Stroke.
Patients with ICD-9-CM Principal or Other Diagnosis Codes of Obstetrics or VTE.
Patients with ICD-9-CM Principal Procedure Code of Surgical Care Improvement Project (SCIP) VTE
selected surgeries
 
VTE-2: ICU Venous Thromboembolism Prophylaxis, VTE-3: Venous Thromboembolism Patients with
Anticoagulation Overlap Therapy, VTE-4: Venous Thromboembolism Patients Receiving Unfractionated
Heparin with Dosages/Platelet Count Monitoring, VTE-5: Venous Thromboembolism Warfarin Therapy Discharge
Instructions and VTE-6: Hospital Acquired Potentially-Preventable Venous Thromboembolism that are used in
The Joint Commission’s accreditation process. 
 
Steward: The Joint Commission.
Use in Federal Program: Hospital Inpatient Quality Reporting, Meaningful Use Stage 2 (EHR Incentive Program) -
Hospitals, CAHs.
Care Setting: Hospital/Acute Care Facility.
National Quality Forum-endorsed measure. Source
 
 
Published By: Elsevier
 No Prophylaxis
 Venous thromboembolism prophylaxis not required - document reason in patient chart
 Venous thromboembolism prophylaxis contraindicated - document reason in patient chart
 Mechanical Devices
 Mechanical methods of prophylaxis against deep vein thrombosis (DVT) such as graduated
compression stockings (GCS) and/or intermittent pneumatic compression (IPC) should be used
primarily in patients at high risk for bleeding 
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Guidance
Mechanical Methods, Deep Vein Thrombosis Prophylaxis
Published guidelines have different recommendations on the use of mechanical compression devices to
prevent deep vein thrombosis:
The American College of Chest Physicians recommends using mechanical thromboprophylaxis with
graduated compression stockings (Grade 2C) or intermittent pneumatic compression (Grade 2C) rather
than no mechanical thromboprophylaxis for acutely ill hospitalized medical patients at increased risk of
thrombosis who are bleeding or at high risk for major bleeding
When bleeding risk decreases, and venous thromboembolism risk persists, these guidelines suggest
substituting pharmacologic thromboprophylaxis for mechanical thromboprophylaxis. (Grade 2B)
The American College of Physicians recommends against the use of mechanical prophylaxis with
graduated compression stockings (GCS). (Strong recommendation, moderate-quality evidence)
A systematic review found that GCS are effective in reducing the risk of DVT, but the evidence is
stronger for general and orthopedic surgery patients than medical patients.
In addition, a systematic review suggests that thigh-high stockings were non-statistically more effective
than knee-high stocking, but patient preference may increase the likelihood of using knee-high
stockings.
 Do not offer anti-embolism stockings to people who have:
Suspected or proven peripheral arterial disease
Peripheral arterial bypass grafting
Peripheral neuropathy or other causes of sensory impairment
Any local conditions in which anti-embolism stockings may cause damage – for example, fragile ‘tissue
paper’ skin, dermatitis, gangrene or recent skin graft
Known allergy to material of manufacture
Severe leg edema
Major limb deformity or unusual leg size or shape preventing correct fit
 Do not offer anti-embolism stockings for VTE prophylaxis to people who are admitted for acute
stroke.  Consider intermittent pneumatic compression for VTE prophylaxis for people who are immobile and
admitted with acute stroke. If using, start it within 3 days of acute stroke
 
Guyatt GH, Akl EA, Crowther M, et al. Executive summary: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Chest. 2012;141(2 Suppl), 7s-47s. Source
 
Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P . Clinical Guidelines Committee of the American
College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice
guideline from the American College of Physicians. Ann Intern Med. 2011;155(9), 625-632. Source
 
Wade R, Paton F, Rice S, et al. Thigh length versus knee length antiembolism stockings for the prevention of
deep vein thrombosis in postoperative surgical patients; a systematic review and network meta-analysis. BMJ
open. 2016;6(2), e009456. Source
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Sachdeva A et al. Graduated compression stockings for prevention of deep vein thrombosis. Cochrane
Database Syst Rev. 12, CD001484, 2014. Source
Published By: Elsevier
 Apply sequential compression device
 Apply thigh-high graduated compression stockings
 Apply knee-high graduated compression stockings
 Medications
 Medical patients at increased risk of DVT should receive thromboprophylaxis with LMWH, LDUH, or
fondaparinux as soon as no high risk of bleeding is present 
Guidance
Prevention of VTE in Hospitalized Acutely Ill Medical Patients
According to American College of Chest Physicians Practice Guidelines:
Use anticoagulant thromboprophylaxis with low-molecular-weight heparin (LMWH), low-dose
unfractionated heparin (UFH) 2 or 3 times per day, or fondaparinux in acutely ill hospitalized medical
patients at increased risk of thrombosis
Do not use pharmacologic or mechanical prophylaxis in acutely ill, hospitalized medical patients at low
risk of thrombosis. (Grade: 1B)
Do not use anticoagulant thromboprophylaxis for acutely ill hospitalized medical patients who are
bleeding or at high risk for bleeding. (Grade: 1B)
Use mechanical thromboprophylaxis with graduated compression stockings (grade: 2C) or intermittent
pneumatic compression (Grade: 2C) rather than no mechanical thromboprophylaxis in acutely
ill hospitalized medical patients at increased risk of thrombosis who are bleeding or at high risk of major
bleeding. When bleeding risk decreases and venous thromboembolism risk persists, substitute
pharmacologic thromboprophylaxis for mechanical thromboprophylaxis. (Grade: 2B)
Do not extend the duration of thromboprophylaxis beyond the period of patient immobilization or acute
hospital stay in acutely ill hospitalized medical patients who receive an initial course of
thromboprophylaxis. (Grade: 2B)
The ACCP recommends the Padua Prediction Score for judging hospitalized patients’ risk. The Padua
Prediction Score assigns points to
the 11 risk factors below. A cumulative score of 4 points or higher constitutes a high risk of venous thromboemb
Padua Prediction Score is available here.
 
American Society of Hematology (ASH) Guidelines
Acutely ill medical patients:  ASH suggests using UFH, LMWH, or fondaparinux rather than no
parenteral anticoagulant. (Conditional recommendation, low certainty in the evidence of effects)
Critically ill medical patients:  AHS recommends using UFH or LMWH over no UFH or LMWH (strong
recommendation, moderate certainty in the evidence of effects) and suggests using LMWH over UFH.
(Conditional recommendation, moderate certainty in the evidence of effects)
DOAC vs LMWH in acutely ill medical patients:
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In acutely ill hospitalized medical patients, the ASH guideline panel recommends using LMWH
over DOACs for VTE prophylaxis. (Strong recommendation, moderate certainty in the evidence
of effects)
In acutely ill hospitalized medical patients, the ASH guideline panel recommends inpatient VTE
prophylaxis with LMWH only, rather than inpatient and extended-duration outpatient VTE
prophylaxis with DOACs. (Strong recommendation, moderate certainty in the evidence of
effects)
The American College of Physicians (ACP) guideline differ slightly from those of the American College of
Chest Physicians, particularly with respect to the use of mechanical prophylaxis. According to the ACP:
Individually assess the risks of thromboembolism and bleeding in medical patients before administering
prophylaxis. (Strong recommendation, moderate-quality evidence)
Administer pharmacologic prophylaxis with heparin or a related drug in medical patients (including
those with stroke), unless the risk of bleeding exceeds the likely benefits.(Strong recommendation,
moderate-quality evidence)
Do not administer mechanical prophylaxis with graduated compression stockings. (Strong
recommendation, moderate-quality evidence). In patients at high risk for bleeding events or in whom
heparin is contraindicated for other reasons, intermittent pneumatic compression may be a reasonable
option
 
The National Institute for Health and Care Excellence (NICE) guideline recommends to:
 Screen patients with an approved tool. The NICE recommended tool can be found here
Offer pharmacological VTE prophylaxis for a minimum of 7 days to acutely ill medical patients whose
risk of VTE outweighs their risk of bleeding:
Use low-molecular-weight heparin (LMWH) as first-line treatment
If LMWH is contraindicated use fondaparinux sodium
 If using pharmacological VTE prophylaxis for people with renal impairment choose either LMWH or
unfractionated heparin (UFH)
 If needed, reduce the dose of LMWH and UFH for people with renal impairment. Base the decision on
multidisciplinary or senior opinion, or locally agreed protocols
Specific recommendations for people with cancer, under palliative care, admitted to critical care, and who have
psychiatric illness are found in the NICE guideline.
 
Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P . Clinical Guidelines Committee of the American
College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice
guideline from the American College of Physicians. Ann Intern Med. 2011;155(9), 625-632. Source
 
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians
Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl), 7S-47S. Source
 
National Institute for Health and Care Excellence (NICE). (2019). Venous thromboembolism in over 16s:
reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Source
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 Schünemann HJ, Cushman M, Burnett AE, et al. American Society of Hematology 2018 guidelines for
management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.
Blood Adv. 2018;2(22), 3198-3225. Source
Published By: Elsevier
 Modify the dose of enoxaparin in patients with severe renal insufficiency (CrCl less than 30 mL/min)
and morbidly obese patients (BMI greater than or equal to 35 mg/m2) 
Guidance
Enoxaparin, DVT Prophylaxis - Medical
For venous thromboembolism (VTE) prophylaxis including deep venous thrombosis (DVT) prophylaxis
or pulmonary embolism prophylaxis:
 
For general medical adult patients with risk factors for DVT due to restrictive mobility during acute illness, e.g.
Moderate to severe congestive heart failure
Severe respiratory disease
Patients who are confined to bed and have 1 or more of the following risk factors:
Active cancer
History of VTE
Sepsis
Acute neurological disease
Inflammatory bowel disease
Adults: 40 mg subcutaneous daily for up to 14 days
For thrombosis prophylaxis in patients with obesity:
NOTE: Although previous clinical practice guidelines recommended weight-based dosing for VTE prophylaxis
in obese patients, current guidelines do not provide specific dosing recommendations but suggest an
increased dose may be required.
Adults: 0.5 mg/kg subcutaneous once or twice daily
Anti-factor Xa concentrations may be monitored with dosage adjustments considered to achieve an
anti-factor Xa concentration of 0.2—0.5 International Units/mL
 
For patients with a CrCl less than 30 mL/minute:
Adults: 30 mg subcutaneously once daily
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For thrombosis prophylaxis in perioperative patients, pregnant females, and patients that need interruption in
vitamin K antagonists (VKA) therapy, consult the reference.
Enoxaparin Drug Monograph. ClinicalKey. 
Nutescu EA, Spinler SA, Wittkowsky A, et al. Low-molecular-weight heparins in renal impairment and obesity:
available evidence and clinical practice recommendations across medical and surgical settings. Ann
Pharmacother. 2009;43(6), 1064-1083. Source
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 Enoxaparin Subcutaneous Injectable Solution; 40 mg Every 24 hours
 Avoid the use of fondaparinux in patients weighing less than 50 kg, the elderly, and frail patients
Guidance
Fondaparinux, DVT Prophylaxis
Avoid the use of fondaparinux in patients weighing <50 kg, the elderly, and frail patients because bleeding
complications may be increased.
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl), e278S-e325S. Source
Published By: Elsevier
 fondaparinux Subcutaneous Prefilled Syringe; 2.5 mg Every 24 hours
 heparin Subcutaneous Injectable Solution; 5000 Units Every 8 hours
Laboratory 
Guidance
Laboratory Testing, COVID-19 ~
Laboratory testing recommendations:
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Positive identification of SARS-CoV-2 (2019-nCoV) RNA by polymerase chain reaction test is considered
confirmation of diagnosis
Routine blood work is not diagnostic, but a pattern of typical abnormalities is emerging in case series of
hospitalized patients:
Leukopenia may be observed and relative lymphopenia is common, especially in patients with
more severe illness
Anemia was noted in about half of patients in one series
Both elevated and low platelet counts have been seen
A prolonged prothrombin time has been reported
Levels of D-dimer and fibrinogen may be elevated
Elevated levels of lactate dehydrogenase and liver enzymes (ALT and AST) are common
Serum procalcitonin levels are usually within reference range; elevated levels have been seen in
patients with secondary infection
Serum levels of some other acute phase reactants (eg, C-reactive protein, ferritin) are elevated in
most patients, as is the erythrocyte sedimentation rate
Lactate level of 2 mmol/L or higher suggests presence of septic shock
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
Published By: Elsevier
 Chemistry
 Lab: Basic Metabolic Profile, Once
 Lab: Comprehensive Metabolic Panel, Once
 Lab: Brain Natriuretic Peptide, Once
 Lab: C-Reactive Protein, Once
 Lab: D-Dimer, Quantitative, Once
 Lab: Fibrinogen , Once
 Lab: Ferritin , Once
 Lab: Hepatic Function Panel , Once
 Lab: Lactic Acid, Venous, Once 
Guidance
Lactate, COVID-19 ~
Lactate level of 2 mmol/L or higher suggests presence of septic shock
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
Published By: Elsevier
 Lab: Lipid Panel, Once
 Lab: Procalcitonin , Once
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 Lab: Troponin I , Once 
Guidance
Blood Chemistry, Non-ST-elevation Acute Coronary Syndrome
AHA/ACC Recommendations for Biomarkers Used for Prognosis, Early Risk Stratification and Diagnosis:
 
Class I Recommendation
Serial cardiac troponin I or T levels (when a contemporary assay is used) should be obtained at
presentation and 3 to 6 hours after symptom onset in all patients who present with symptoms
consistent with ACS to identify a rising and/or falling pattern of values. (Level of Evidence: A)
Additional troponin levels should be obtained beyond 6 hours after symptom onset in patients with
normal troponin levels on serial examination when changes on ECG and/or clinical presentation confer
an intermediate or high index of suspicion for ACS. (Level of Evidence: A)
If the time of symptom onset is ambiguous, the time of presentation should be considered the time of
onset for assessing troponin values. (Level of Evidence: A)
The presence and magnitude of troponin elevations are useful for short- and long-term
prognosis. (Level of Evidence: B)
 
Class IIa Recommendation
It is reasonable to obtain a fasting lipid profile in patients with NSTE-ACS, preferably within 24 hours of
presentation. (Level of Evidence: C)
 
Class IIb
Measurement of B-type natriuretic peptide or N-terminal pro–B-type natriuretic peptide may be
considered to assess risk in patients with suspected ACS. (Level of Evidence: B)
 
Class III: No Benefit
With contemporary troponin assays, creatine kinase myocardial isoenzyme (CK-MB) and myoglobin
are not useful for diagnosis of ACS. (Level of Evidence: A)
 
Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients With
Non–ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines. Circulation. 2014;130, e344-e426. Source
Published By: Elsevier
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 Hematology
 Lab: Complete Blood Count (CBC), Once
 Lab: Erythrocyte sedimentation rate (ESR) , Once
 Lab: Glycohemoglobin A1C, Once
 Lab: Prothrombin time (PT) with INR, Once
 Lab: Prothrombin time (PT) with INR, Every morning
 Lab: Partial Thromboplastin Time, Once
 Microbiology
 Blood culture, Once (1 of 2)
 Blood culture, Once (2 of 2)
 Gram stain, culture and sensitivity, Sputum, Once 
Guidance
Sputum Testing, COVID-19 ~
Collect a sputum specimen if a productive cough is present:
 
Lower respiratory tract
A deep cough sputum specimen (collected after mouth rinse) is also acceptable
WHO advises against attempts to induce sputum, because the process may increase
aerosolization and risk of transmission
 
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
Published By: Elsevier
 Gram stain, culture and sensitivity, Urine, Once
 Influenza A/B PCR, Nose , Once 
Guidance
Influenza A/B Antigen, Respiratory Illness ~
Nasal Influenza A and B virus antigen
Obtain nasal swab samples to test for influenza in patients with suspected viral pneumonia
Use a rapid influenza diagnostic test if it will change the care of the patient or of other patients. The
following factors warrant such testing:
Hospitalized patients
Patients with high-risk conditions
Documentation of institutional outbreaks
Elsevier © 2020 6 May 2020
Atypical timing (eg, summer months in temperate climates)
Under these circumstances, viral culture is recommended to confirm positive results
from rapid tests and to identify strain
Antigen detection tests: rapid influenza diagnostic tests are usually available at the point of care
Performed on nasal or nasopharyngeal swab or aspirate
Some can distinguish influenza A from influenza B but cannot identify specific strain
Sensitivity is 50% to 70%
Specificity is 90% to 95%
Influenza Clinical Overview. ClinicalKey. 
Community-Acquired Pneumonia in Adults Clinical Overview. ClinicalKey.  
Published By: Elsevier
 Influenza A/B PCR, Sputum , Once
 Methicillin-resistant S. aureus (MRSA) Culture, Nose, Once
 Mycoplasma pneumoniae Culture, Sputum , Once
 Contact Local Public Health Department for Positive SARS-CoV-2 Polymerase Chain Reaction
results
 Real-Time Polymerase chain reaction for SARS-CoV-2; Nasopharyngeal swab, Once 
Guidance
Pharyngeal Swab, COVID-19 ~
CDC provides specific instructions for collection and handling of specimens.
Upper Respiratory Tract Swab
Nasopharyngeal swab is preferred; oropharyngeal swab may be submitted in addition, if obtained. Only
synthetic fiber swabs with plastic shafts are acceptable. If both are submitted, they may be placed in
the same container
For nasopharyngeal specimen, insert swab into nostril parallel to palate. Leave swab in place for a few
seconds to absorb secretions
For oropharyngeal specimen, swab the posterior pharynx, avoiding tongue and tonsils
ClinicalKey. (2020). Coronavirus: novel coronavirus (COVID-19) infection. Source
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 Real-Time Polymerase chain reaction for SARS-CoV-2; Oropharyngeal swab, Once 
Guidance
Pharyngeal Swab, COVID-19 ~
CDC provides specific instructions for collection and handling of specimens.
Upper Respiratory Tract Swab
Nasopharyngeal swab is preferred; oropharyngeal swab may be submitted in addition, if obtained. Only
synthetic fiber swabs with plastic shafts are acceptable. If both are submitted, they may be placed in
the same container
For nasopharyngeal specimen, insert swab into nostril parallel to palate. Leave swab in place for a few
seconds to absorb secretions
For oropharyngeal specimen, swab the posterior pharynx, avoiding tongue and tonsils
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 Real-time polymerase chain reaction (RT-PCR), sputum , Once ; For SARS-CoV-2
 Respiratory Syncytial Virus (RSV) Antigen, Nose , Once
 Urine
 Lab: Urinalysis, Once
 Lab: Pregnancy Test, Urine, Once
 Lab: Drug Screen, Urine , Once
Radiology 
Guidance
Imaging, COVID-19 ~
Chest imaging (eg, plain radiography, CT) has shown abnormalities in most reported patients; it usually shows
bilateral involvement, varying from consolidation in more severely ill patients to ground-glass opacities in less
severe and recovering pneumonia
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 Plain Films
 X-ray, Chest PA/lateral, Once; History: [add diagnosis, symptom(s)]; Question: [add reason for
study]
 X-ray, Chest PA (Portable), Once; History: [add diagnosis, symptom(s)]; Question: [add reason for
study]
 CT Scan 
Guidance
CT Scan, COVID-19 ~
CT appears to be more sensitive than plain radiographs, but normal CT appearance does not exclude COVID-19
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 CT, Chest with IV contrast ; History: [add diagnosis, symptom(s)] ; Question: [add reason for study]
 CT, Chest without IV contrast ; History: [add diagnosis, symptom(s)] ; Question: [add reason for
study]
Diagnostic Studies
 Electrocardiogram, with at least 12 leads ; History: [add diagnosis, symptom(s)] ; Question: [add
reason for study]
Consults
 Consult: Public Health ; History: [add reason for consult] ; Question: [add reason for consult] ; further
evaluation and management
 Consult: Infectious Disease ; History: [add diagnosis, symptom(s)] ; Question: [add reason for consult]
; further evaluation and management 
Guidance
Infectious Disease Referral, COVID-19 ~
Consult infectious disease specialist to coordinate diagnosis and management with public health authorities
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 Consult: Pulmonary Medicine (Pulmonology) ; History: [add diagnosis, symptom(s)] ; Question: [add
reason for consult] ; further evaluation and management 
Guidance
Pulmonology Referral, COVID-19 ~
Consult pulmonologist to aid in obtaining deep specimens for diagnosis and managing mechanical ventilation if
necessary
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 Consult: Clinical Social Work; History: [add diagnosis, symptom(s)]; Question: [add reason for consult]
 Consult: Dietitian; History: [add diagnosis, symptom(s)]; Question: [add reason for consult]
 Consult: Pharmacy; History: [add diagnosis, symptom(s)]; Question: [add reason for consult]
 Consult: Occupational Therapy; History: [add diagnosis, symptom(s)]; Question: [add reason for
consult]
 Consult: Physical Therapy; History: [add diagnosis, symptom(s)]; Question: [add reason for consult]
Modules 
Guidance
COVID-19 Module Use, COVID-19 ~
Please note that the Medication Infusion Module and the Mechanical Ventilation Module are not COVID-specific.
COVID-specific guidance is below:
Medication Infusion
Management of septic shock includes use of vasopressors if fluid administration does not restore adequate
perfusion. Surviving Sepsis Campaign, NIH COVID-19 treatment guideline, and WHO provide guidance specific
to the treatment of shock in patients with COVID-19
In adults, begin with norepinephrine; epinephrine or vasopressin are preferred as second line over
dopamine if norepinephrine is unavailable
Hemodynamic goal: mean arterial pressure of 60 to 65 mm Hg
In patients who do not respond adequately to usual doses of norepinephrine, Surviving Sepsis Campaign
guideline on managing critically ill adults with COVID-19 recommends adding vasopressin rather than
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further titrating norepinephrine
For patients with COVID-19, refractory shock despite fluid and norepinephrine, and evidence of cardiac
dysfunction, Surviving Sepsis Campaign guideline on managing critically ill adults with COVID-19
recommends adding dobutamine rather than further titrating norepinephrine
In children, epinephrine is considered the first line agent, and norepinephrine may be added if necessary
WHO, NIH, and Surviving Sepsis Campaign provide specific guidance for oxygenation, ventilation, and
fluid management in COVID-19
Patients with severe respiratory distress, obstructed or absent breathing, central cyanosis, shock,
seizures, or coma require aggressive airway management (which may include intubation) and oxygen
Oxygenation and ventilation
Begin supplemental oxygen when O₂ saturation falls below 90% to 92%
Nasal cannula at 5 L/minute or face mask with reservoir bag at 10 to 15 L/minute
Titrate to reach SpO₂ of 94% or more initially
Once stable, target SpO₂ of 90% or higher in nonpregnant adults; 92% or higher in
pregnant patients
In most children the target SpO₂ is 90% or greater; for those who require urgent
resuscitation (eg, those with apnea or obstructed breathing, severe respiratory distress,
central cyanosis, shock, seizures, or coma), a target SpO₂ of 94% or higher is
recommended
High-flow nasal oxygen or noninvasive ventilation has been used to achieve adequate oxygenation
in some patients
High-flow nasal oxygen is recommended by Surviving Sepsis Campaign and NIH for
COVID-19 patients who develop hypoxemic respiratory failure despite conventional oxygen
therapy; there is some evidence that it averts the need for intubation and mechanical
ventilation. Noninvasive positive pressure ventilation may be used if high-flow nasal
oxygen is not available
However, there is concern that these techniques may result in higher risk of aerosolization
of the virus. Additionally, sudden deterioration may require emergent intubation, which is
associated with more risk to both patient and provider. Therefore, some authorities reserve
these options for settings in which airborne precautions can be taken and close monitoring
provided
Mechanical ventilation may become necessary for patients in whom oxygenation targets cannot be
met with less invasive measures or who cannot maintain the work of breathing
Recommended settings are tidal volume of 4 to 8 mL/kg (predicted body weight) and
inspiratory pressures less than 30 cm H₂O
In children, tidal volumes of 5 to 8 mL/kg (predicted body weight) for preserved lung
compliance and 3 to 6 mL/kg for poor compliance; inspiratory pressures should be less
than 28 cm H₂O
Use of PEEP may be necessary in patients with acute respiratory distress syndrome.
Optimal regimen is not clearly defined, although guidelines suggest higher pressures (eg,
more than 10 cm H₂O) rather than lower pressures. A protocol is available from ARDSnet
For patients with moderate to severe acute respiratory distress syndrome, prone
positioning for 12 to 16 hours/day is recommended
Lateral decubitus position for pregnant women
Extracorporeal membrane oxygenation has been used in severely ill patients, and it can be
considered if resources and expertise are available
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 Glucose Management - Module
 Respiratory Therapy - Module
 Immunizations, Adult - Module
 Smoking Cessation/Tobacco Withdrawal - Inpatient Module
 Pressure Injury Management - Module
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